Neuropeptide Y (NPY) is a highly potent orexigenic substance that is also known to modulate gonadotropin secretion. Five receptor subtypes for NPY have been identified, and a potent antagonist for the receptor subtype 1 (Y1), 1229U91, also known as GW1229 or GR231118, has been described. Subsequently, 1229U91 was also shown to represent a highly potent agonist for the Y4 receptor subtype. Very unexpectedly, intracerebroventricular administration of 1229U91 elicited an intense, dose-dependent surge of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in intact male rats that lasted for 6 h. Such stimulation was absent when a potent gonadotropin-releasing hormone antagonist was administered systemically, suggesting that 1229U91 acts centrally to stimulate gonadotropin-releasing hormone release. 1229U91 administration had no effect on growth hormone, thyroid-stimulating hormone, and corticosterone secretions. In addition to 1229U91, four other parent dimer molecules described earlier produced a marked and sustained stimulation of LH when injected intracerebroventricularly that was proportional to their binding affinity for the Y4 receptor. Central administration of the specific Y1 antagonist BIBO3304 (20 µg) had no effect on LH secretion, making it unlikely for 1229U91 to stimulate LH secretion by an antagonistic action on the Y1 receptor subtype, thus suggesting a Y4 receptor mediation. In conclusion, the 1229U91 molecule displays an interesting conformational epitope that is able to generate large LH surges, possibly by activating Y4 or Y4-like receptor subtypes or by acting on a NPY receptor unrelated target.

Keywords:
Neuropeptide Y, Neuropeptide Y receptors, Gonadotropins, Gonadotropin-releasing hormone
1.
Tatemoto K, Carlquist M, Mutt V: Neuropeptide Y – a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;285:417–418.
2.
Danger JM, Tonon MC, Jenks BG, Saint-Pierre S, Martel JC, Fasolo A, Breton B, Quirion R, Pelletier G, Vaudry H: Neuropeptide Y: Localization in the central nervous system and neuroendocrine functions. Fundam Clin Pharmacol 1990;4:307–340.
3.
Stanley BG, Leibowitz SF: Neuropeptide Y injected in the paraventricular nucleus: A powerful stimulant of feeding behaviour. Proc Natl Acad Sci USA 1985;82:3940–3943.
4.
Kalra SP, Crowley WR: Norepinephrine-like effects of neuropeptide Y in the rat. Life Sci 1984;35:1173–1176.
5.
McDonald JK, Lumpkin MD, DePaolo LV: Neuropeptide Y suppresses pulsatile secretion of luteinizing hormone in ovariectomized rats: Possible site of action. Endocrinology 1989;125:186–191.
6.
Kalra SP: Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr Rev 1993;14:507–538.
7.
Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML: Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993;132:224–234.
8.
Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in adult male rats. Endocrinology 1996;137:3–12.
9.
Blomqvist AG, Herzog H: Y-receptor subtypes – how many more? Trends Neurosci 1997;20:294–298.
10.
Gehlert DR: Multiple receptors for the pancreatic polypeptide (PP-fold) family: Physiological implications. Proc Soc Exp Biol Med 1998;218:7–22.
11.
Wyss P, Stricker-Krongrad A, Brunner L, Miller A, Crossthwaite A, Whitebread S, Criscione L: The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 1998;75–76:363–371.
12.
Kalra SP, Fuentes M, Fournier A, Parker SL, Crowley WR: Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats. Endocrinology 1992;130:3323–3330.
13.
Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML: Evidence that the inhibition of LH secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominently mediated by the NPY-Y5 receptor subtype. Endocrinology 1999;140:4046–4055.
14.
Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA: Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP3226. J Pharmacol Exp Ther 1995;275:136–142.
15.
Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN: Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 1998;125:549–555.
16.
Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A: High-affinity neuropeptide Y antagonists. Proc Natl Acad Sci USA 1995;92:9067–9071.
17.
Rüeger H, Schmidlin T, Rigollier P, Yamaguchi Y, Tintelnot-Blomley M, Schilling W, Criscione L, Mah R: Receptor Antagonists. Novartis AG Patent WO 97/20823. Example No. 53, p 91, 1997.
18.
Bitran M, Daniels AJ, Boric MP: 1229U91, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstriction effect of neuropeptide Y in the hamster microcirculation. Eur J Pharmacol 1997;319:43–47.
19.
Kanatani A, Ishihara A, Asahi S, Tanaka T, Ozaki S, Ihara M: Potent neuropeptide Y Y1 receptor antagonist, 1229U91: Blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 1996;137:3177–3182.
20.
Ishihara A, Tanaka T, Kanatani A, Fukami M, Ihara M, Fukuroda T: A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am J Physiol 1998;274:R1500–R1504.
21.
Gehlert DR, Schober DA, Beavers L, Gadski R, Hoffmann JA, Smiley DL, Chance RE, Lundell I, Larhammar D: Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol Pharmacol 1996;50:112–118.
22.
Parker EM, Babij CK, Balasubramanian A, Burrier RE, Guzzi M, Hamud F, Mukhopadhyay G, Rudinski MS, Tao Z, Tice M, Xia L, Mullins DE, Salisbury BG: GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y-1 receptor antagonists and neuropeptide Y Y-4 receptor agonists. Eur J Pharmacol 1998;349:97–105.
23.
Schober DA, Van Abbema AM, Smiley DL, Bruns RF, Gehlert DR: The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide preferring (NPY Y4) receptor. Peptide 1998;19:537–542.
24.
Daniels AJ, Heyer D, Landavazo A, Leban JJ, Spaltenstein A: Patent Cooperation Treaty (PCT) Publ. WO94/00486, 1994.
25.
Broqua P, Aebi AC, Jiang GC, Stalewski J, Semple G, Akinsanya K, Haigh R, Riviere P, Rivier J, Aubert ML, Junien JL: Pharmacological profile of FE200486, a potent, water-soluble and long-acting GnRH antagonist (abstract 18). 5th Int Symp on GnRH Analogues in Cancer and Human Reproduction, Geneva 1999.
26.
Cheng Y, Prusoff W: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099–3108.
27.
Kalra SP, Crowley WR: Differential effects of pancreatic polypeptide on luteinizing hormone release in female rats. Neuroendocrinology 1984;38:511–513.
28.
Kalra PS, Jain MR, Pu S, Kalra SP: NPY and GnRH: A role of Y4 and coexpressed GABA (abstract). 5th Int NPY Meeting, Grand Cayman Island 1999, p 30.
29.
Jain MR, Pu S, Kalra PS, Kalra SP: Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology 1999;140:5171–5177.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.